Verrica Pharmaceuticals Inc
General ticker "VRCA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $44.5M
Verrica Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -26.0%.
Estimated limits based on current volatility of 5.3%: low 0.65$, high 0.72$
Factors to consider:
- Current price 80.5% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.60$, 7.96$]
- 2024-12-30 to 2025-12-30 estimated range: [3.44$, 7.58$]
Financial Metrics affecting the VRCA estimates:
- Negative: Non-GAAP EPS, $ of -1.14 <= 0.10
- Negative: Operating profit margin, % of -92.77 <= 1.03
- Negative: Operating cash flow per share per price, % of -15.72 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.01 <= 1.31
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
Short-term VRCA quotes
Long-term VRCA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $12.00MM | $9.03MM | $5.12MM |
| Operating Expenses | $42.91MM | $30.33MM | $70.88MM |
| Operating Income | $-30.91MM | $-21.30MM | $-65.76MM |
| Non-Operating Income | $-4.17MM | $-3.19MM | $-1.24MM |
| Interest Expense | $4.29MM | $2.17MM | $3.96MM |
| R&D Expense | $15.93MM | $12.20MM | $20.30MM |
| Income(Loss) | $-35.08MM | $-24.49MM | $-67.00MM |
| Profit(Loss) | $-35.08MM | $-24.49MM | $-67.00MM |
| Stockholders Equity | $32.60MM | $40.03MM | $19.76MM |
| Inventory | $0.00MM | $0.49MM | $1.02MM |
| Assets | $80.12MM | $44.72MM | $81.60MM |
| Operating Cash Flow | $-27.58MM | $-18.65MM | $-38.58MM |
| Capital expenditure | $0.88MM | $0.30MM | $0.36MM |
| Investing Cash Flow | $-1.00MM | $54.04MM | $-0.36MM |
| Financing Cash Flow | $33.65MM | $-16.87MM | $74.21MM |
| Earnings Per Share* | $-1.44 | $-0.81 | $-1.48 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.